

SOLUBLE ISCHEMIA ACTIVATED PROTEIN

INV: O. MIROCHNITCHENKO, ET AL.

SN: 09/960,631

01/07

#4





Fig. 1

SOLUBLE ISCHEMIA ACTIVATED PROTEIN
INV. O. MIROCHNITCHENKO, ET AL.
SN: 09/960,631

02/07



Upper panel: Northern blot hybridized with candidate gene probe
Lower panel: the same blot hybridized with mouse GAPDH gene probe, shown as internal control

Fig. 2

SOLUBLE ISCHEMIA ACTIVATED PROTEIN
INV: O. MIROCHNITCHENKO, ET AL.
SN: 09/960,631

03/07




Fig. 3

SOLUBLE ISCHEMIA ACTIVATED PROTEIN
INV: O. MIROCHNITCHENKO, ET AL.
SN: 09/960,631

04/07

1. Molecular marker
2. Total cell extract
3. 20,000g ppt after sonication
4. 180,000g ppt
5. 20% $(\text{NH}_4)_2\text{SO}_4$ ppt
6. 40% $(\text{NH}_4)_2\text{SO}_4$ ppt
7. 6-% $(\text{NH}_4)_2\text{SO}_4$ ppt

→ IAP





Fig. 4

05/07

mRNA expression in mouse tissues



mRNA expression after kidney ischemia/reperfusion




Fig. 5


SOLUBLE ISCHEMIA ACTIVATED PROTEIN

INV: O. MIROCHNITCHENKO, ET AL.

SN: 09/960,631

06/07

MEASUREMENT OF IAP mRNA
ACTIVATION DURING KIDNEY I/R *



* AT LEAST 4 ANIMALS WERE ANALYZED PER EACH GROUP.

Fig. 6

SOLUBLE ISCHEMIA ACTIVATED PROTEIN
INV: O. MIROCHNITCHENKO, ET AL
SN: 09/960,631

07/07

Overexpression of IAP in Hela cells




Fig. 7